Have any questions? 706-721-6582 or cts@augusta.edu
- (The PROMISE Study) A prospective study to evaluate biological and clinical effects of significantly corrected CFTR function
Clinical Trial
(The PROMISE Study) A prospective study to evaluate biological and clinical effects of significantly corrected CFTR function
The PROMISE study is for people with CF whose doctors intend to treat them using a new drug for their condition. This new drug is a combination of three drugs. The Promise study will collection information and specimens before and after this therapy is started.
Eligibility Criteria
- Males and females age 12 years of age and older Documented diagnosis of Cystic Fibrosis Enrolled in Cystic Fibrosis Foundation National Patient Registry CFTR mutations consistent with the FDA labeled indication for the new Vertex CFTR modulator TCT (triple combination therapy) Is being treated by a physician intending to prescribe the new Vertex CFTR modulator TCT
RESEARCH. INNOVATION. DISCOVERY.